A Novel Somatostatin-Dopamine Chimera (BIM23B065) Reduced GH Secretion in a First-in-Human Clinical Trial.
Wadim M I de Boon , Michiel J van Esdonk , Frederik E Stuurman , Nienke R Biermasz
The Journal of Clinical Endocrinology and Metabolism 104 ( 3) 883 -891
8
2019
Effects of erythropoietin on cycling performance of well trained cyclists : a double-blind, randomised, placebo-controlled trial
Jules A A C Heuberger , Joris I Rotmans , Pim Gal , Frederik E Stuurman
The Lancet Haematology 4 ( 8)
28
2017
Erythropoietin on cycling performance - Authors' reply.
Jules A A C Heuberger , Joris I Rotmans , Pim Gal , Frederik E Stuurman
The Lancet Haematology 4 ( 10)
1
2017
Objective home-monitoring of physical activity, cardiovascular parameters, and sleep in pediatric obesity
Janine M Knijff , Euphemia CAM Houdijk , Daniëlle van der Kaay , Youri van Berkel
Digital biomarkers 6 ( 1) 19 -30
1
2022
Randomized phase I trial of antigen-specific tolerizing immunotherapy with peptide/calcitriol liposomes in ACPA+ rheumatoid arthritis
Amee Sonigra , Hendrik J Nel , Pascale Wehr , Nishta Ramnoruth
JCI insight 7 ( 20)
18
2022
An exploratory first‐in‐man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2‐and 1‐week interval in patients with metastatic castration resistant prostate cancer
Josephina PM Vrouwe , Ingrid MC Kamerling , Michiel J van Esdonk , Josbert M Metselaar
Pharmacology Research & Perspectives 9 ( 5) e00845 -e00845
2
2021
each lactate threshold concept in gxt1 and time trial test 1 (tt1), gxt4 and time trial test 2 (tt2) and gxt5 and average road race (rr) power for all subjects combined. All correlations are significant (p< 0.0002). To determine potential differences in power output between the lt concept and time trial power or race power, mean difference (sd) between each measurement pair is calculated. Negative values indicate lactate threshold power is higher than exercise test average power.
Jules AAC Heuberger , Jelle J Posthuma , Dimitrios Ziagkos , Joris I Rotmans
the clinical pharmacology of and doping detection in sports 126 -126
Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs
Guilherme S Ferreira , Francis M Dijkstra , Désirée H Veening-Griffioen , Wouter PC Boon
Translational Psychiatry 13 ( 1) 74 -74
1
2023
and specificity of detection methods for erythropoietin doping in cyclists
Jules AAC Heuberger , Peter van Eenoo , Joris I Rotmans , Pim Gal
the clinical pharmacology of and doping detection in sports 146 -146
Sensitivity and specificity of detection methods for erythropoietin doping in cyclists.
Jules AAC Heuberger , Peter Van Eenoo , Joris I Rotmans , Pim Gal
Drug Testing and Analysis 11 ( 9) 1290 -1301
3
2019
Clinical validation of digital biomarkers for paediatric patients with asthma and cystic fibrosis: potential for clinical trials and clinical care
Matthijs D Kruizinga , Esmée Essers , Frederik E Stuurman , Yalçin Yavuz
European Respiratory Journal 59 ( 6)
6
2022
Smartphone-Based Passive Sensing in Monitoring Patients With Cancer: A Systematic Review
Dominique G Stuijt , Igor Radanovic , Milan Kos , Jan W Schoones
JCO clinical cancer informatics 7 e2300141 -e2300141
2023
The effects of intranasal esketamine on on-road driving performance in patients with major depressive disorder or persistent depressive disorder
Francis M Dijkstra , Aurora Jae van de Loo , Smedra Abdulahad , Else R Bosma
Journal of psychopharmacology 36 ( 5) 614 -625
6
2022
Development and technical validation of a smartphone‐based pediatric cough detection algorithm
Matthijs D Kruizinga , Ahnjili Zhuparris , Eva Dessing , Fas J Krol
Pediatric pulmonology 57 ( 3) 761 -767
11
2022
Theoretical performance of nonlinear mixed-effect models incorporating saliva as an alternative sampling matrix for therapeutic drug monitoring in pediatrics: a simulation study
Matthijs D Kruizinga , Frederik E Stuurman , Gertjan JA Driessen , Adam F Cohen
Therapeutic Drug Monitoring 43 ( 4) 546 -554
6
2021
A phase 1 dose‐escalation study of low‐dose metronomic treatment with novel Oral paclitaxel formulations in combination with ritonavir in patients with advanced solid tumors
Vincent A de Weger , Marit AC Vermunt , Frederik E Stuurman , Artur M Burylo
Clinical Pharmacology in Drug Development 10 ( 6) 607 -621
8
2021
A phase I dose-escalation study of low dose-metronomic chemotherapy with oral paclitaxel in combination with ritonavir (ModraPac001/r and ModraPac005/r).
Vincent A de Weger , Frederik E Stuurman , Artur Burylo , Jeroen JMA Hendrikx
Clinical pharmacology of novel anticancer agents 119 -119
2017
Technical validity and usability of a novel smartphone-connected spirometry device for pediatric patients with asthma and cystic fibrosis.
Matthijs D. Kruizinga , Esmée Essers , F. E. Stuurman , Ahnjili Zhuparris
Pediatric Pulmonology 55 ( 9) 2463 -2470
2
2020
Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors
F. E. Stuurman , E. E. Voest , A. Awada , P. O. Witteveen
Investigational New Drugs 31 ( 4) 959 -966
28
2013
Development of Novel, Value-Based, Digital Endpoints for Clinical Trials: A Structured Approach Toward Fit-for-Purpose Validation.
M. D. Kruizinga , F. E. Stuurman , V. Exadaktylos , R. J. Doll
Pharmacological Reviews 72 ( 4) 899 -909
25
2020